BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...Genomics Inc. Mesa has Emergency Use Authorization from FDA for its 30-minute point-of-care COVID-19 diagnostic. Orexo AB...
...BioCentury Staff PTC Therapeutics Inc. uniQure N.V. Sangamo BioSciences Inc. TCR2 Therapeutics Inc. Five Prime Therapeutics Inc. Evelo Biosciences Inc. Magenta Therapeutics Inc. Orexo AB Imago...
BioCentury | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

...and hired Quentin Durand as chief legal officer. Durand was a lawyer at Dechert LLP. Orexo AB...
...B.V. Alligator Bioscience AB Biocon Ltd. Intercept Pharmaceuticals Inc. Nektar Therapeutics Agios Pharmaceuticals Inc. Accelerate Diagnostics Inc. Rheostat Therapeutics Tricida Inc. Revance Therapeutics Inc. Poxel S.A. Orexo AB Homology...
BioCentury | Nov 27, 2019
Company News

Nov. 27 Company Quick Takes: Orexo, GAIA in second deal for substance abuse digital therapy; plus PDUFA date for Verrica's skin infection candidate and $25M fol

...Orexo gets U.S. rights to GAIA's alcohol abuse digital therapeutic Orexo AB (SSE:ORX) licensed exclusive U.S. rights...
...AG to vorvida, a digital therapeutic to treat alcohol use disorder; financial terms are undisclosed. Orexo...
...intended to enhance the use of Orexo's Zubsolv buprenorphine/naloxone to treat opioid use disorder (see "Orexo...
BioCentury | Aug 21, 2019
Company News

Orexo, GAIA to develop digital therapeutic for opioid use disorder

...Via a deal with German digital therapeutics company GAIA, Orexo will develop a psychosocial support product...
...of Zubsolv buprenorphine/naloxone, its treatment for opioid use disorder (OUD). For its first digital therapeutic, Orexo AB...
...provides simulated interactions with a virtual counselor available around the clock to patients with OUD, Orexo...
BioCentury | Apr 12, 2019
Product Development

Changing models and minds to improve access to addiction treatment

...couple payment for the treatment to improved patient outcomes and benefits to the healthcare system. Orexo AB...
...$200 or $300 per visit, if you’re homeless, that’s a lot of money.” Nikolaj Sørensen, Orexo...
...insurance coverage has led some to only accept cash payments for some therapies, such as Orexo’s...
BioCentury | Apr 5, 2019
Product Development

Reaching addiction patients where they’re at

...Washington, D.C. Erin McCallister, Senior Editor Vivitrol, naltrexone (Medisorb naltrexone, Vivitrex, XR-NTX) Zubsolv, buprenorphine/naloxone (OX219, PKX219) Alkermes National Institutes of Health Orexo AB opioid...
BioCentury | Dec 21, 2018
Company News

Orexo regains ex-U.S. rights to Zubsolv from Mundipharma

...global, ex-U.S. rights to Zubsolv buprenorphine/naloxone from Mundipharma International Ltd. (Dublin, Ireland), effective April 13. Orexo...
...Mundipharma. Zubsolv is a sublingual tablet of buprenorphine and naloxone marketed to treat opioid dependence. Orexo AB...
...SSE:ORX), Uppsala, Sweden Mundipharma International Ltd., Dublin, Ireland Business: Neurology Shannon Lehnbeuter Zubsolv, buprenorphine/naloxone (OX219, PKX219) Mundipharma International Ltd. Orexo AB...
BioCentury | Oct 26, 2018
Company News

Management tracks: Principia, Orexo, Polyphor, MeiraGTx

...of translational medicine for immunology, inflammation and infectious disease at Roche (SIX:ROG; OTCQX:RHHBY). Neurology company Orexo AB...
...Larsen. Juuel is succeeded by Joseph DeFeo, who is VP of finance and administration at Orexo’s...
BioCentury | May 31, 2018
Company News

Management tracks: Axcella, Arcturus, Orexo

...to distract shareholders from the company’s share price. CFO Henrik Juuel will depart neurology company Orexo AB...
...SSE:ORX) in November to join vaccine company Bavarian Nordic A/S (CSE:BAVA) as EVP and CFO. Orexo...
BioCentury | May 17, 2018
Finance

Europe’s piece of the pie

...year, cancer antibody-drug conjugate company ADCendo ApS and obesity startup Antag Therapeutics ApS. In Sweden, Orexo AB...
...MolMed S.p.A. (Milan:MLM), Milan, Italy Novo Holdings A/S, Hellerup, Denmark Orchard Therapeutics Ltd., London, U.K. Orexo AB...
Items per page:
1 - 10 of 273
BioCentury | Apr 18, 2020
Management Tracks

PTC names Matthew Klein as chief development officer; plus Cardurion, Sangamo, TCR2, Five Prime and more

...Genomics Inc. Mesa has Emergency Use Authorization from FDA for its 30-minute point-of-care COVID-19 diagnostic. Orexo AB...
...BioCentury Staff PTC Therapeutics Inc. uniQure N.V. Sangamo BioSciences Inc. TCR2 Therapeutics Inc. Five Prime Therapeutics Inc. Evelo Biosciences Inc. Magenta Therapeutics Inc. Orexo AB Imago...
BioCentury | Dec 4, 2019
Company News

Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more

...and hired Quentin Durand as chief legal officer. Durand was a lawyer at Dechert LLP. Orexo AB...
...B.V. Alligator Bioscience AB Biocon Ltd. Intercept Pharmaceuticals Inc. Nektar Therapeutics Agios Pharmaceuticals Inc. Accelerate Diagnostics Inc. Rheostat Therapeutics Tricida Inc. Revance Therapeutics Inc. Poxel S.A. Orexo AB Homology...
BioCentury | Nov 27, 2019
Company News

Nov. 27 Company Quick Takes: Orexo, GAIA in second deal for substance abuse digital therapy; plus PDUFA date for Verrica's skin infection candidate and $25M fol

...Orexo gets U.S. rights to GAIA's alcohol abuse digital therapeutic Orexo AB (SSE:ORX) licensed exclusive U.S. rights...
...AG to vorvida, a digital therapeutic to treat alcohol use disorder; financial terms are undisclosed. Orexo...
...intended to enhance the use of Orexo's Zubsolv buprenorphine/naloxone to treat opioid use disorder (see "Orexo...
BioCentury | Aug 21, 2019
Company News

Orexo, GAIA to develop digital therapeutic for opioid use disorder

...Via a deal with German digital therapeutics company GAIA, Orexo will develop a psychosocial support product...
...of Zubsolv buprenorphine/naloxone, its treatment for opioid use disorder (OUD). For its first digital therapeutic, Orexo AB...
...provides simulated interactions with a virtual counselor available around the clock to patients with OUD, Orexo...
BioCentury | Apr 12, 2019
Product Development

Changing models and minds to improve access to addiction treatment

...couple payment for the treatment to improved patient outcomes and benefits to the healthcare system. Orexo AB...
...$200 or $300 per visit, if you’re homeless, that’s a lot of money.” Nikolaj Sørensen, Orexo...
...insurance coverage has led some to only accept cash payments for some therapies, such as Orexo’s...
BioCentury | Apr 5, 2019
Product Development

Reaching addiction patients where they’re at

...Washington, D.C. Erin McCallister, Senior Editor Vivitrol, naltrexone (Medisorb naltrexone, Vivitrex, XR-NTX) Zubsolv, buprenorphine/naloxone (OX219, PKX219) Alkermes National Institutes of Health Orexo AB opioid...
BioCentury | Dec 21, 2018
Company News

Orexo regains ex-U.S. rights to Zubsolv from Mundipharma

...global, ex-U.S. rights to Zubsolv buprenorphine/naloxone from Mundipharma International Ltd. (Dublin, Ireland), effective April 13. Orexo...
...Mundipharma. Zubsolv is a sublingual tablet of buprenorphine and naloxone marketed to treat opioid dependence. Orexo AB...
...SSE:ORX), Uppsala, Sweden Mundipharma International Ltd., Dublin, Ireland Business: Neurology Shannon Lehnbeuter Zubsolv, buprenorphine/naloxone (OX219, PKX219) Mundipharma International Ltd. Orexo AB...
BioCentury | Oct 26, 2018
Company News

Management tracks: Principia, Orexo, Polyphor, MeiraGTx

...of translational medicine for immunology, inflammation and infectious disease at Roche (SIX:ROG; OTCQX:RHHBY). Neurology company Orexo AB...
...Larsen. Juuel is succeeded by Joseph DeFeo, who is VP of finance and administration at Orexo’s...
BioCentury | May 31, 2018
Company News

Management tracks: Axcella, Arcturus, Orexo

...to distract shareholders from the company’s share price. CFO Henrik Juuel will depart neurology company Orexo AB...
...SSE:ORX) in November to join vaccine company Bavarian Nordic A/S (CSE:BAVA) as EVP and CFO. Orexo...
BioCentury | May 17, 2018
Finance

Europe’s piece of the pie

...year, cancer antibody-drug conjugate company ADCendo ApS and obesity startup Antag Therapeutics ApS. In Sweden, Orexo AB...
...MolMed S.p.A. (Milan:MLM), Milan, Italy Novo Holdings A/S, Hellerup, Denmark Orchard Therapeutics Ltd., London, U.K. Orexo AB...
Items per page:
1 - 10 of 273